Patent 10987368 was granted and assigned to Glycom A/S on April, 2021 by the United States Patent and Trademark Office.
The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.